Baxter International Inc.
BAXBaxter sits at the heart of hospital care, yet its future depends on rebuilding profitability in a low-margin, highly regulated business.
Because essential products do not automatically mean durable profits.
Business Model
Devices plus disposables
Baxter sells medical machines and the steady stream of supplies and fluids that go with them.
Economic Engine
High volume, low margin
Large recurring hospital demand drives revenue, but profits depend on tight cost control.
Long-Term Lens
Operational turnaround
The key question is whether management can restore margins and consistent cash generation.
On this page
Company Story
How do Baxter International Inc.'s business model and economics hold up on a closer read?
Start with the business itself, then go one layer deeper into the model, the economics, and the long-term case.
“Baxter is a critical healthcare supplier with durable demand, but its shrinking margins and weak cash conversion must be fixed to unlock long-term value.”
What does Baxter International Inc. actually do?
Baxter International makes medical products that hospitals use every day to treat patients.
- Produces intravenous fluids and nutrition bags used in surgeries and emergencies
- Manufactures dialysis equipment and supplies for patients with kidney failure
- Sells infusion pumps and other devices that deliver drugs safely
Why it matters
Essential hospital infrastructure
These products are routine and necessary in modern healthcare, creating steady baseline demand.
How does Baxter International Inc. make money?
Baxter makes money by selling medical devices and the ongoing disposable supplies that hospitals must reorder.
- Upfront sales of equipment such as infusion pumps and dialysis machines
- Recurring sales of fluids, tubing, and other single-use supplies
- Long-term relationships with hospitals and clinics around the world
Economic clue
30.1% gross margin
A gross margin of 30.1% shows this is a competitive, cost-sensitive business rather than a high-margin monopoly.
Why do long-term investors keep Baxter International Inc. on the radar?
Baxter serves fundamental healthcare needs that are unlikely to disappear over the next 20 years.
- Aging populations increase demand for dialysis and hospital procedures
- Chronic diseases require ongoing treatment and fluid management
- Global healthcare spending continues to rise over time
Investor takeaway
Stable demand, unstable profits
Revenue grew 5.7% year-over-year, but margins are contracting and net margin is negative 8.5%, highlighting the gap between demand and profitability.
Based on company financial statements.
Benchmark Comparison
How has Baxter International Inc. performed against common long-term benchmarks?
Once the business case is clear, compare the stock against broad market and alternative long-term baselines.
$226.62
-77.3% total return
$1,753
+75.3% total return
$2,975
+197.5% total return
$1,393
+39.3% total return
| Asset | Total Return | Dollar Value |
|---|---|---|
| BAX | -77.3% | $226.62 |
| S&P 500 | +75.3% | $1,753 |
| Gold | +197.5% | $2,975 |
| Bitcoin | +39.3% | $1,393 |
From Mar 5, 2021 to Mar 6, 2026. Historical price data based on company financial statements and market indices. Each card uses the same starting amount so the comparison stays apples-to-apples.
Investor Fit
How a first-time investor could frame Baxter International Inc.
Before going deeper, decide what kind of business this is, what it tends to suit, and what deserves monitoring over time.
This Can Fit If You Want
- Exposure to essential healthcare infrastructure
- A potential multi-year operational turnaround story
- Steady underlying demand driven by aging demographics
Be Careful If You Expect
- High and stable profit margins
- Strong cash generation relative to accounting earnings
- Rapid double-digit revenue growth over many years
What To Watch Over Time
- Whether operating margin turns sustainably positive from negative 2.7%
- Improvement in free cash flow compared to net income, currently negative 0.34 times
- Five-year revenue trend, which has averaged negative 1.9% growth
Key Metrics
Which metrics matter most for Baxter International Inc. right now?
Three durable business metrics that matter more than day-to-day price moves.
Negative 1.9% five-year average, 5.7% year-over-year
37.8% year-over-year
30.1% gross margin, negative 8.5% net margin
| Metric | Value | Context |
|---|---|---|
| Revenue Growth | Negative 1.9% five-year average, 5.7% year-over-year | Shows that long-term expansion has been weak even though recent growth has turned positive. |
| EPS Growth | 37.8% year-over-year | Earnings per share improved year-over-year, but sustainability depends on margin recovery. |
| Margin Quality | 30.1% gross margin, negative 8.5% net margin | Highlights the gap between product-level profitability and overall losses after expenses. |
Based on company financial statements.
Fundamentals
What do Baxter International Inc.'s fundamentals say right now?
Core financial markers that explain how the business is performing beneath the stock price.
-0.9% ROIC
30.1% gross margin
2.9% FCF margin
Stable to shrinking
| Metric | Value | Interpretation |
|---|---|---|
| Capital Efficiency | -0.9% ROIC | The business is currently showing poor capital efficiency. |
| Profitability | 30.1% gross margin | Healthy gross margins give the company room to invest, price competitively, and absorb shocks. |
| Cash Generation | 2.9% FCF margin | Free cash flow margin shows how much real cash the business keeps after funding operations and investment. |
| Ownership Trend | Stable to shrinking | The company is not currently diluting owners and may be buying back shares instead. |
Based on company financial statements.
Included In Funds
Which ETFs and funds currently hold Baxter International Inc.?
Baxter International Inc. currently appears in these ETF and fund proxies.
SPY
SPDR S&P 500 ETF Trust
IWB
iShares Russell 1000 ETF
Questions & Answers
What questions come up most often about Baxter International Inc.?
Company-specific questions readers often ask about Baxter International Inc..
Each entry answers a direct question about the business, the long-term thesis, or the risks that matter over time.
Baxter International makes and sells medical products such as IV fluids, dialysis equipment, and infusion pumps that hospitals and clinics use daily.
Decision Framing
Secondary context after the long-term thesis
Shorter-horizon context and comparison tools, after the core long-term read.
Shorter-horizon price moves, two-sided debate, and comparison tools live here so the page stays anchored on business quality, durability, and BinaPrint fit first.
Investment Thesis
Bull vs Bear
Two-sided framing before any decision.
Current argument weight is balanced.
Bull case
What can work
Aging populations and rising rates of chronic kidney disease create steady long-term demand for dialysis equipment and related supplies.
Hospitals prefer reliable, established suppliers for critical products like IV fluids, creating moderate switching costs due to training, contracts, and regulatory approvals.
With 38,000 employees and global scale, Baxter can leverage manufacturing and distribution networks to improve efficiency if operations are streamlined.
If operating margin improves from negative 2.7% to even mid single digits, the earnings power could expand meaningfully without requiring explosive revenue growth.
Bear case
What can break
Medical supplies such as IV fluids and basic equipment can become commoditized, leading to price competition that keeps gross margin near 30% or lower.
Regulatory or quality control failures in sterile products could lead to recalls, fines, or reputational damage that permanently hurt demand.
Technological shifts toward new treatment methods or home-based care models could reduce reliance on traditional hospital equipment over 20 years.
Persistent negative net margins, currently negative 8.5%, could strain the balance sheet if not reversed.
Risk Radar
Key Risks
Where downside pressure can build.
Profitability risk: Net margin is negative 8.5%, so sustained losses could erode capital over time.
Cash flow risk: Free cash flow is only 2.9% of revenue and is negative 0.34 times net income, limiting financial flexibility.
Growth risk: Five-year average revenue growth is negative 1.9%, indicating difficulty expanding the business.
Sizing matters
Risks should be read as scenario inputs, not certainties. Position size and time horizon determine how much of this downside profile is acceptable.
Market Snapshot
Tactical context after the core long-term read.
- Price
- $17.69
- Daily move
- -4.89%
Peer Set
A compact peer list for side-by-side context.
Next Actions
Explore planning scenarios or keep browsing similar companies.